Home » Pipeline
Pipeline
Company | Drug/Device | Medical Condition | Status |
---|---|---|---|
COVID-19 Trials and Actions | |||
OncoSec Medical | CORVax12 | DNA-encodable vaccine against SARS-CoV-2 | IND approved by the FDA |
Equillium | itolizumab | hospitalized COVID-19 patients with acute respiratory distress syndrome (ARDS) | IND approved by FDA for phase 3 trial |
Symvivo Corporation | bacTRL-spike oral vaccine | prevention of COVID-19 | first patient dosed in phase 1 trial |
RevImmune | CYT107 (recombinant human Interleukin-7) | patients critically ill with COVID-19 | patient enrollment initiated in the U.S. in phase 2 trial |
Humanigen | lenzilumab | prevention of cytokine storm in hospitalized patients with COVID-19 | first patient dosed in phase 3 trial |
Other Trials and Actions | |||
enGene | EG-70 | Bacille Calmette-Guerin (BCG)-unresponsive nonmuscle-invasive bladder cancer | IND approved by the FDA |
InnoCare Pharma | orelabrutinib | multiple sclerosis | IND approved by the FDA |
Neuraly | NLY01 | Alzheimer’s disease | IND approved by the FDA |
OliX Pharmaceuticals | OLX10010 | adjunct therapy to reduce the recurrence of hypertrophic scars after scar revision surgery | IND approved by the FDA |
TaiGen Biotechnology | TG-1000 | influenza A and B | IND approved by the FDA |
Aligos Therapeutics | ALG-000184 | chronic hepatitis B virus | first patient dosed in phase 1a/1b trial |
BiomX | BX002 | inflammatory bowel disease | first patient dosed in phase 1a trial |
Synlogic | SYNB8802 | enteric hyperoxaluria | first patient dosed in phase 1 trial |
MindMed | LSD microdose and experiential doses | anxiety disorders | completion of phase 1 trial |
Q32 Bio | ADX-914 | autoimmune diseases | first patient dosed in phase 1 trial |
ADC Therapeutics | camidanlumab tesirine (ADCT-301) in combination with pembrolizumab | select advanced solid tumors | first patients dosed in combination arm of phase 1b trial |
Gritstone Oncology | GRANITE and SLATE (neoantigen-based immunotherapies) | historically cold (or non-immunogenic) tumor types | first patients dosed in phase 2 expansion cohorts of phase 1/2 trials |
Rubius Therapeutics | RTX-240 | acute myeloid leukemia | first patient dosed in phase 1/2 trial |
Novus Therapeutics | AT-1501 | amyotrophic lateral sclerosis | first patient enrolled in phase 2a trial |
AIVITA Biomedical | AV-GBM-1 | glioblastoma | patient dosing complete in phase 2 trial |
Amino Technology | PalinGen Flow | adults with chronic ulcers of the lower extremities due to venous stasis or diabetic etiologies | initiation of phase 2 trial |
NanOlogy | NanoPac (sterile nanoparticulate paclitaxel) for suspension via intratumoral injection | prostate cancer | first patient enrolled in phase 2 trial |
PolyActiva | latanoprost-free-acid sustained-release ocular implant | glaucoma | initiation of phase 2 trial in Australia |
Enlivix | Allocetra | sepsis | approval received from the Israeli Ministry of Health for a phase 2b trial |
Pfizer | vupanorsen (AKCEA-ANGPTL3-LRx) | patients with elevated nonhigh-density lipoprotein cholesterol (nonHDL-C) and triglycerides | initiation of phase 2b trial |
Asieris Pharmaceuticals | APL-1202 | nonmuscle-invasive bladder cancer | approval granted by the Center for Drug Evaluation of the China National Medical Products Administration to initiate phase 3 trial |
Cerevel Therapeutics | tavapadon | Parkinson’s disease | first patients dosed in three phase 3 trials |
Concert Pharmaceuticals | CTP-543 | moderate-to-severe alopecia areata | initiation of phase 3 trial |
Daiichi Sankyo AstraZeneca |
Enhertu (fam-trastuzumab deruxtecan-nxki) | adjuvant therapy in patients with HER2-positive early breast cancer with high risk of disease recurrence who have residual invasive disease in the breast or axillary lymph nodes after receiving neo-adjuvant therapy | initiation of phase 3 trial |
GW Pharmaceuticals Greenwich Biosciences |
nabiximols | multiple sclerosis-associated spasticity | initiation of phase 3 trial |
LianBio | infigratinib | locally advanced or metastatic unresectable cholangiocarcinoma with FGFR2 gene fusions | approval granted by the Center for Drug Evaluation of the China National Medical Products Administration to initiate phase 3 trial |
Logic Bio | LB-001 | methylmalonic acidemia | Fast-Track designation granted by the FDA |
Rafael Pharmaceuticals | CPI-613 (devimistat) | soft tissue sarcoma | Orphan Drug designation granted by the FDA |
Boston Scientific | Ranger drug-coated balloon | patients with peripheral artery disease in the superficial femoral artery and proximal popliteal artery | approved by the FDA |
Chiesi, USA | Bronchitol (mannitol) inhalation powder | add-on maintenance therapy to improve pulmonary function in cystic fibrosis patients 18 years of age and older | approved by the FDA |
Upcoming Events
-
14May
-
23May
-
21Oct